Undisclosed cell therapy (Immatics)

Undisclosed cell therapy (Immatics) refers to a research-stage program within the Immatics pipeline for which the specific molecular target and primary clinical indications remain confidential. As a cell therapy developed by Immatics, the program likely leverages the company's expertise in T-cell receptor (TCR) based therapies. Immatics typically utilizes its XPRESIDENT discovery platform to identify tumor-associated peptides presented by HLA molecules, which are then targeted using engineered T-cell products (such as ACTengine or ACTallo). This specific asset is categorized separately from their lead PRAME-targeting programs, indicating it targets a different, currently undisclosed antigen.

Other names

Immatics-other-cell therapy-undisclosedUndisclosed cell therapy